107220-28-0

• 常用中文名：((+/-)-顺式-2-甲基螺[1,3-氧硫杂环戊烷-5,3'-奎宁环]盐酸半水合物
• 常用英文名：Cevimeline hydrochloride
• CAS号：107220-28-0
• 分子式：C₁₀H₁₈ClNOS
• 分子量：235.774
• 相关类别： 信号通路 G 蛋白偶联受体/G 蛋白 由mAChR
• 发布时间：2017-01-07 19:56:25
• 更新时间：2024-01-02 12:11:04
• Cevimeline (Evoxac)盐酸盐是mAChR激动剂。

名称

• 中文名: ((+/-)-顺式-2-甲基螺[1,3-氧硫杂环戊烷-5,3'-奎宁环]盐酸半水合物
• 英文名: 2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane],hydrochloride
• 英文别名: (2R,2'R)-2'-méthylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] chlorhydrate; (2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] hydrochloride; (2R,2'R)-2'-Methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] hydrochloride (1:1); (2R,2'R)-2'-Methylspiro[4-azabicyclo[2.2.2]octan-2,5'-[1,3]oxathiolan]hydrochlorid; Cevimeline Hydrochloride Salt; AF 102B hydrochloride; Spiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane], 2'-methyl-, (2'R,3R)-, hydrochloride (1:1); spiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane], 2'-methyl-, (2'R,3R)-, hydrochloride; Cevimeline hydrochloride

物化性质

• 沸点: 308.5ºC at 760mmHg
• 分子式: C₁₀H₁₈ClNOS
• 分子量: 235.774
• 闪点: 140.4ºC
• 精确质量: 235.079758
• PSA: 37.77000
• LogP: 2.30010
• 蒸汽压: 0.000676mmHg at 25°C
• 储存条件: 2-8℃

生物活性

• 描述: Cevimeline (Evoxac)盐酸盐是mAChR激动剂。
• 相关类别:
  信号通路 >> G 蛋白偶联受体/G 蛋白 >> 由mAChR
  信号通路 >> 神经信号通路 >> mAChR
  研究领域 >> 神经疾病
• 参考文献:

  [1]. Witsell DL, et al. Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia.Head Neck. 2012 Aug;34(8):1136-42. doi: 10.1002/hed.21894. Epub 2012 Jan 9.

  [2]. Ono K, et al. Distinct effects of cevimeline and pilocarpine on salivary mechanisms, cardiovascular response and thirst sensation in rats.Arch Oral Biol. 2012 Apr;57(4):421-8. Epub 2011 Nov 17.

  [3]. Kondo Y, et al.Cevimeline-induced monophasic salivation from the mouse submandibular gland: decreased Na+ content in saliva results from specific and early activation of Na+/H+ exchange.J Pharmacol Exp Ther. 2011 Apr;337(1):267-74. Epub 2011 Jan 14.

  [4]. Voskoboynik B, et al.Cevimeline (Evoxac) overdose.J Med Toxicol. 2011 Mar;7(1):57-9.

  [5]. Tajiri S, et al. Dosage form design and in vitro/in vivo evaluation of cevimeline extended-release tablet formulations.Int J Pharm. 2010 Jan 4;383(1-2):99-105. Epub 2009 Sep 10.